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KIDNEY CANCER: CASE REPORT
Durable Remission with Immunotherapy in a Patient with  
Sarcomatoid Renal Cell Carcinoma 
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Department of Hematology and Oncology, Beaumont Health, Royal Oak, MI, USA
Abstract 
Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal 
cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, che-
motherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with 
sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. 
RCCs with sarcomatoid differentiation have a high presence of programmed cell death protein 1 and programmed cell death ligand 1 in T cells 
and tumor cells, respectively, making immunotherapy an attractive option in this setting. Clinical trials are ongoing to further define the benefit 
of immunotherapy in sarcomatoid RCC. 
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A 73-year-old man presented to our facility with complaints 
of left upper quadrant pain and twenty-pound weight loss. 
A computed tomographic (CT) scan of the chest, abdo-
men, and pelvis revealed a huge upper quadrant complex 
mass (Figure 1A), whereas a biopsy of the mass revealed 
high-grade malignant neoplasm. He underwent radical 
nephrectomy, splenectomy, and resection of the diaphragm. 
Pathology revealed a 23.5 cm mass with histologic grade 4 
renal cell carcinoma (RCC) with sarcomatoid (95%) and 
focal papillary (1%) features that invaded into the peri-
nephric fat, gerota fascia, spleen, and diaphragm, all with 
negative margins, translating to a pathological stage 4. 
On immunohistochemistry, the tumor stained positive for 
CK  7, PAX-8, and CD-10, whereas AE1/AE3 was focally 
positive (Figure 1B–E). Three months postnephrectomy, he 
complained of pleuritic chest pain. A CT scan of the chest 
revealed abnormal tissue in the inferior posterior left pleural 
Immunotherapy in sarcomatoid renal cell carcinoma









Figure 1: Radiologic and pathologic findings.
space, and left-sided abdominal and peritoneal lymph nodes. 
Biopsy revealed sarcomatoid RCC. He received radiation 
therapy to that region and subsequent chemotherapy with 
sunitinib and gemcitabine. A repeat CT of the chest, abdo-
men, and pelvis 6 months after therapy initiation revealed no 
evidence of disease. 
Unfortunately, 9 months after chemotherapy initiation, 
the patient noted a tender subcutaneous nodule in the left 
chest wall. CT scan of the chest revealed a new irregular 
area of pleural soft tissue at the posterior medial aspect of 
the left lower lobe of the lung (Figure 1G). A positron emis-
sion tomography (PET) scan revealed multiple suspicious 
retrocrural and left aortic lymph nodes with intense 18F-flu-
orodeoxyglucose (FDG) avidity, in addition to several FDG-
avid soft tissue lesions in the left chest and abdominal wall. 
He underwent radiation to the left abdominal wall and due 
to his high PD-1 and PD-L1 status he was prescribed pem-
brolizumab, which he received for only 3 months because of 
grade 4 immune-mediated pneumonitis. Repeat PET scans 
showed interval resolution of the previous lesions in the peri-
toneal and retroperitoneal cavities and the posterior left cost-
ophrenic angle, indicating a favorable response to therapy. 
Recent PET scans after more than 4 years of immunotherapy 
revealed no evidence of recurrent disease.
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Discussion 
Sarcomatoid RCC is a rare histologic subtype, present in 
5%-8% of all RCCs (1). It is aggressive with a poor prognosis 
and overall survival of approximately 4 months when diag-
nosed at an advanced stage (2). Sarcomatoid RCC can also 
be seen in combination with other subtypes of RCC, where 
a higher percentage of sarcomatoid features confers a worse 
prognosis (3). Surgical resection is curative in early-stage dis-
ease. However, in advanced disease, there is typically a rapid 
onset of relapse despite complete surgical resection. In a ret-
rospective review of patients with metastatic chromophobe 
RCC, patients with sarcomatoid features versus those without 
had a statistically significant shorter median time to metastatic 
disease relapse after nephrectomy for localized disease (2.7 
months vs. 48.8 months) and treatment failure during first-line 
treatment (1.8 months vs. 8 months) when compared with those 
without sarcomatoid features (4). Chemotherapeutic agents 
have limited success in producing response or durable remis-
sion. In a phase 2 trial of doxorubicin and gemcitabine in 39 
patients with sarcomatoid RCC, 16% of patients experienced 
response, whereas 26% had stable disease. The median pro-
gression-free survival (PFS) was 3.5 months, and the median 
overall survival (OS) was 8.8 months (5). Tyrosine kinase 
inhibitors, mammalian target of rapamycin (mTOR) inhib-
itors, and vascular endothelial growth factor inhibitors with 
chemotherapy have been utilized with modest improvement in 
survival (6,7). In a phase 2 trial of capecitabine, gemcitabine, 
and bevacizumab in patients with metastatic or unresectable 
sarcomatoid RCC, the response rate remained low, with only 
20% of the participants achieving a response and only one 
patient with a complete response. The median PFS in this trial 
was 5.5 months, and the median OS was 12 months. About 
91% of patients discontinued treatment because of treat-
ment-related toxicity, commonly noted with combination ther-
apies (7). In a retrospective study of patients with sarcomatoid 
RCC who received sunitinib, PFS was 5.7 months, with only 
30% of patients achieving stable disease (1). In another retro-
spective study assessing the benefit of mTOR inhibitors in 23 
patients with sarcomatoid RCC, the median PFS and OS were 
3.5 months and 8.2 months, respectively (6). 
RCCs with sarcomatoid differentiation have been noted 
to have 89% programmed cell death ligand 1 (PDL-1) posi-
tivity and combined PDL-1 and programmed cell death pro-
tein-1 positivity of 50% (8). Despite this, studies have shown 
conflicting responses to immunotherapy. In a retrospective 
review of patients with sarcomatoid RCC treated with immu-
notherapy versus chemotherapy, a triple improvement in the 
median PFS in the immunotherapy group and no difference 
in OS was observed (9). In a single case report, a notably 
durable remission of about 2 years was seen in a patient who 
received nivolumab (10). Our patient achieved an ongoing 
4-year remission after treatment with pembrolizumab. 
The phase 3 Checkmate 426 trial comparing the combined 
targeted agents axitinib and pembrolizumab versus sunitinib 
in 105 patients with sarcomatoid RCC showed impressive 
results in favor of combined axitinib and pembrolizumab. 
There was an almost doubling of the objective response 
rate (ORR, 58.8% vs. 31.5%) and a complete response rate 
(CRR) of 11.8% vs. 0%. The 12-month overall OS showed 
a 42% reduction in the risk for death in favor of pembroli-
zumab and axitinib (83.4% vs. 79.5%) (11). 
In the recent phase 3 Checkmate 214 trial, which compared 
dual immunotherapy (nivolumab and ipilimumab) with suni-
tinib, in patients with advanced RCC with sarcomatoid fea-
tures the median OS was not reached at a minimum follow-up 
of 42 months in the immunotherapy arm compared with 14.2 
months in the sunitinib arm, which translated to a statisti-
cally significant 55% reduction in the risk for death with dual 
immunotherapy. In addition to the impressive OS benefit, the 
ORR and CRR were 2.6 and 6.1 times higher, respectively, 
than with sunitinib (60.8% vs. 23.1% and 18.9% vs. 3.1%) (12).
Considering these impressive data, an immune check-
point-based regimen should be the initial choice in the 
management of patients with metastatic or advanced sarco-
matoid RCC over local therapies like nephrectomy and radi-
ation therapy. 
Patients are encouraged to participate in clinical trials for 
further treatment developments with improved efficacy and 
limited toxicities. Currently, clinical trials are in progress 
using immunotherapy and immunotherapy in combination 
with targeted agents to define the benefits of immunotherapy 
in sarcomatoid RCC. However, patient accrual in these trials 
may be difficult because of the rarity of this histologic sub-
type. Umbrella trials are an effective means of investigating 
different cancers with sarcomatoid histology to assess bio-
markers and treatment options (Table 1). 
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